Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Nonarteritic Anterior Ischemic Optic Neuropathy

In brief

This study is designed as a double-masked, randomized, placebo-controlled, clinical study to evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in participants with previous NAION. All participants enrolled in Cohort A of the study will have a documented history of NAION for at least 12 months and at most, five years prior to enrollment. Participants enrolled in Cohort B of the study will have a documented history of NAION for at least 6 months and at most, three years prior to enrollment.

Key facts

Study ID
NCT03547206
Run by
Regenera Pharma Ltd
People needed
165
Starts
2018-07-10
Expected to finish
2020-09-27
Last updated by the study team
2020-10-12

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.